ArticleThe British journal of surgery2025
Major systemic infection following breast cancer surgery and oncological outcomes.
Article in The British journal of surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Variation in chemotherapy use across healthcare regions in Sweden and its impact on prognosis in women with HR+/HER2- early breast cancer.Breast cancer research : BCR · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPostoperative infections are well-known complications following cancer surgery and are associated with worse oncological outcomes in several cancer types. The influence of major systemic postoperative infections on the risk of breast cancer recurrence remains unexplored. The primary aim of this study was to assess the risk of distant recurrence following major systemic infection. Secondary aims were to assess this risk after other major events such as stroke, myocardial infarction and pulmonary embolism.
methodsThis nationwide cohort study included patients who underwent breast cancer surgery in Sweden between 2008 and 2019. The study cohort was identified using BCBaSe 3.0, a database linking the Swedish National Breast Cancer Quality Register with other national population-based healthcare registers. The primary exposure was major systemic infection within 90 days of surgery, with a secondary analysis of other major events. The primary outcome was distant recurrence, whereas secondary outcomes included locoregional recurrence, overall survival, and breast cancer-specific survival.
resultsAmong 82 102 patients included, 1.8% (n = 1461) experienced a major systemic infection, and 0.6% (n = 516) other major events within 90 days of surgery. In adjusted analyses, major systemic infection was associated with increased risk of distant recurrence (HR 1.23, 95% c.i. 1.07-1.41), overall death (HR 1.47, 1.32-1.64), breast cancer-specific death (HR 1.27, 1.06-1.51), but not with locoregional recurrence.
conclusionsAt a median follow-up of 4.8 years, major systemic postoperative infections were associated with an increased risk of distant recurrence, overall death, and breast cancer-specific death, highlighting the importance of timely and effective treatment of postoperative infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.